standard (AES) method. The scintillators used were a) dioxan-toluene-ethylcellosolve (75:15:10) containing 4.0 g/liter of PPO, 0.4 g/liter of dimethyl-POPOP, and 100 g/liter of naphthalene, b) toluene containing 4.0 g/liter of PPO and 0.3 g/liter of dimethyl-POPOP.

Acknowledgement The authors are greatly indebted to Dr. Waro Nakahara, Director of this Institute, for his hearty encouragement throughout this work. Thanks are also due to Professor Shigeo Baba of the Tokyo College of Pharmacy and Dr. Tomoyoshi Komai of National Institute of Health (Japan) for their useful discussions. A part of this work was financially supported by a Grant-in-Aid for Cancer Research from the Ministry of Education, which is gratefully acknowledged.

Chem. Pharm. Bull. 18(1) 206—209 (1970)

UDC 612.397-08:612.459-08

## Prostaglandin E<sub>2</sub> like Activity in Monkey Lung<sup>1)</sup>

HIROAKI TSUKATANI, TAKAFUMI ITAMI, and Kunio Matsuda

Faculty of Pharmaceutical Sciences, Tokushima University<sup>2)</sup>

(Received July 28, 1969)

Recently, the occurrence of derivatives of prostaglandin (PG) has been demonstrated in the lungs of some species, such as sheep,<sup>3)</sup> pigs,<sup>3a)</sup> cattle,<sup>4)</sup> guinea pigs,<sup>3a)</sup> monkies,<sup>3a)</sup> and humans.<sup>3a,5)</sup> Prostaglandin F (PGF) series, prostaglandin  $E_{2a}$  (PGF<sub>2a</sub>) was found and identified in the lungs of all species, whereas prostaglandin E (PGE) series, prostaglandin  $E_{2a}$  (PGE<sub>2</sub>) was proved to be present in only two species, namely sheep<sup>3a)</sup> and humans.<sup>5)</sup> The amount of the above compound in these species was found to be approximately one percent of the PGF<sub>2a</sub> content. It seems of interest to investigate the occurrence and the contents of the PGE series compounds in the lungs of other species.

The present paper reports the occurrence of a compound which has a PGE<sub>2</sub> like activity in the lung of monkies (*Macaca irus*), in addition to PGF<sub>2a</sub>, the presence of which in monkey lungs has been previously reported by Äggård.<sup>3a)</sup>

An acidic lipid substance, which stimulates smooth muscle and reduces blood pressure, was separated from monkey lung by the use of organic solvent distribution, column chromatography and thin-layer chromatography (TLC). Treatment of this lipid compound is briefly outlined in Chart 1.

Fig. 1 shows the distribution of smooth muscle stimulating activity of the active component in fraction X on silver nitrate silicagel plate, which was found to be useful for the separation of the derivatives of PG with different degrees of unsaturation to each other.

<sup>9)</sup> Reproducibility was not so good probably due to variation in the activity of alumina catalyst. Details are now being investigated in our laboratory.

<sup>10)</sup> S. Okada and O. Tamemasa, Radioisotopes (Tokyo), 14, 42 (1965).

<sup>1)</sup> Part of this work was presented at the Meeting of the Chugoku-Shikoku Branch, Pharmaceutical Society of Japan, Nov. 1968.

<sup>2)</sup> Location: No. 78, Shomachi-1-chome, Tokushima.

<sup>3)</sup> a) E. Äggård, Biochem. Pharmacol., 14, 1057 (1965); b) S. Bergström, F. Dressler, L. Krabisch, R. Ryhage and J. Sjövall, Arkiv. Kem., 20, 63 (1962); c) E. Äggård and B. Samuelsson, Acta Physiol. Scand., 59, suppl., 213, 170 (1963).

<sup>4)</sup> B. Samuelsson, Biochem. Biophys. Acta (Amst.), 84, 707 (1964).

<sup>5)</sup> S.M.M. Karim, M. Sandler, and E.D. Williams, Brit. J. Pharmacol., 31, 340 (1967).

```
monkey lung
       homogenize and extract with ethanol
ethanol extract I
       concentrate, acidify, and extract with ethyl acetate
ethyl acetate layer II
                             aqueous layer III
       dry and countercurrent distribution between petroleum ether and ethanol-
       water (2:1)
aqueous ethanol layer IV
                                 petroleum ether layer V
       concentrate, acidify, and extract with ethyl acetate
ethyl acetate layer VI
                              aqueous layer VII
       wash with water and dry
crude extract VIII
       silicagel chromatography
active fraction IX
       TLC on silicagel plate; benzene-dioxane-acetic acid (20:20:1)
active fraction X
                                                         active fraction XI
       corresponding to PGE
                                                               corresponding to PGF
       TLC on AgNO<sub>3</sub> impregnated plate; ethyl acetate-acetic
       acid-2,2,4-trimethylpentane-water (110:20:30:100)
  active fraction XII
       corresponding to PGE,
```

Chart 1. Separation Procedure

The Rf value of the active component in fraction X, which was obtained from the active zone corresponding to the PGE group on another silicagel plate, is close to that of authentic PGE<sub>2</sub>.

In addition to strong smooth muscle stimulating activity, the active fraction XII shows a marked depressor activity on rats and rabbits. This strong depressor action of this fraction persists after treatment with atropine, diphenhydramine, or propranolol on rats.

Furthermore, we compared the derivatives of PGE and the active fraction XII with the effects on some isolated smooth musle organs and those on blood pressure in two species. The results are shown in Table 1. The relative activities of fraction XII are parallel to those of PGE<sub>2</sub> in each biological effect. Judging from this result, the active component of fraction XII may be regarded as PGE<sub>2</sub>.

Considering these results, we assume that the isolated material from monkey lung may contain the compound which has the biological and chemical properties closely resembling PGE<sub>2</sub>. Assuming that the active compound is PGE<sub>2</sub>,




Fig. 1. Distribution of Smooth Muscle Stimulating Activity on TLC

Silver nitrate impregnated plate. AcOEt-AcOH-2,2,4-trimethylpentane-water (110:20:30:100) 208 Vol. 18 (1970)

the content of which can be estimated as being approximately  $0.02-0.03 \mu g$  per gram tissue: The result of which was obtained from the recovery of authentic PGE<sub>2</sub> through the same procedure. This content is approximately one per cent of that of PGF<sub>2a</sub><sup>3a)</sup> as in other species.

TABLE I.a)	Comparison of the Biological Activities between the Derivatives of
P	G and the Active Fraction XII on Some Isolated Smooth
	Muscle Organs and the Blood Pressures.

	$PGE_1$	$\mathrm{PGE}_2$	$\mathrm{PGE}_3^{b)}$	Fraction XII	PGE <sub>2</sub> /Fraction XII
Rabbit duodenum	1	5.5	0.5	1.00	5.5
Rat jejenum	1	0.3		0.05	6.0
Rat stomach	1	1.1		0.21	5.2
Guinea pig ileum	1	1.6	0.23	0.27	5.9
Rat uterus	1	1.2	0.31	0.25	4.8
Rat blood pressure	1	0.5		0.10	5.0
Rabbit blood pressure	1	0.6	0.32	0.10	6.0

a) Each value is the average of three experiments and expresses the relative activity in relation to the activity of PGE<sub>1</sub>. As to fraction XII, its aliquot portion is calculated in the same manner. In the last column are shown the ratios of the relative activity of fraction XII to those of PGE<sub>2</sub> in each biological effect.

## Experimental

Material—Monkey Lung: Nine hundred grams of monkey (Macaca~irus) lung obtained at bleeding were kept frozen at  $-20^{\circ}$ . Silicagel plates for TLC: Commercially obtained plates "Spot film silicagel" (Tokyo Kasei Kogyo K.K., Tokyo) were used. Silver nitrate impregnated plate: The "Spot film silicagel" was dipped into a silver nitrate solution ( $40~{\rm g~AgNO_3}+100~{\rm ml~Water}+300~{\rm ml~EtOH}$ ) for one minute, and activated in a vacuum oven at room temperature for one hour prior to use. Silicagel for column chromatography: "Kiesel gel" (Merck, Germany) was activated at  $105^{\circ}$  for one hour before use.

Extraction and Preliminary Separation<sup>3a)</sup>——The lungs were homogenized and four times the volume of 96% ethanol was added. The suspention was left at room temperature over night with stirring. After centrifugation the clear supernatant was siphoned off. The insoluble residue was resuspended in the same volume of 70% ethanol, and after recentrifugation the second clear supernatant was added. The combined ethanol extract was evaporated under reduced pressure to about one twentieth of the original volume. This solution was acidified to pH 3 with 0.1n HCl and then extracted four times with the same volume of ethyl acetate. After washing the combined ethyl acetate layer was evaporated to dryness under reduced pressure. The residue was subjected to a three stage countercurrent distribution between petroleum ether and ethanol—water (2:1). The combined aqueous ethanol layer was evaporated under reduced pressure to about one twentieth of the original volume with nitrogen leak at 40°. This solution was acidified to pH 3 with 0.1n HCl and then extracted four times with the same volume of ethyl acetate. The combined ethyl acetate layer was washed with water to make the solution neutral and evaporated to dryness. These procedures give the crude extract VIII.

Silicagel Chromatography—Two grams of silicagel were suspended in ethyl acetate-benzene (20:80), and poured in the glass column. The obtained crude extract VIII was dissolved in the same solvent and applied to the column. The column was eluted successively with 10 ml of ethyl acetate-benzene (20:80), 40 ml of benzene-dioxane-acetic acid (20:20:1) and 40 ml of methanol. The smooth muscle stimulating activity on isolated rabbit duodenum was concentrated in the second fraction. This active fraction IX was dried under reduced pressure.

Separation of PGE like Substance—PGE like substance was isolated from fraction IX with TLC. The sample was applied on line on the plate with authentic samples on both sides. The plate was developed with benzene-dioxane-acetic acid (20:20:1).6)

After cutting off of the region of authentic samples, the reference spots were detected by spraying with 10% alcoholic phosphomolybdic acid and heating at  $105^{\circ}$  for 15 minutes. The remaining region was scraped off with the range of Rf value 0.016, and the each region was transferred to the test tube. Each sample was extracted with methanol, and aliquot portion of extract was taken, dried and dissolved in saline solution.

b) B. Samuelsson, J. Biol. Chem., 238, 3229 (1963); E. W. Horton and I.H.M. Main, Brit. J. Pharmacol. Chemotherap., 21, 182 (1963)

<sup>6)</sup> K. Green and B. Samuelsson, J. Lipid Res., 5, 117 (1964).

The solution were applied for the assay on isolated rabbit duodenum preparation. Two active zones were found, and their Rf values were found to correspond to those of the PGE group and PGF group respectively. The extracts, corresponding to the PGE group, were combined, dried and applied to further purification.

Separation of PGE<sub>2</sub> like Substance—The active fraction X which showed PGE like activity was further purified with TLC<sup>6</sup>) on silver nitrate impregnated silicagel plate. Fraction X was applied on line with authentic samples of PGE<sub>1</sub> and PGE<sub>2</sub> on both sides. The plate was developed with ethyl acetate-acetic acid-2,2,4-trimethylpentane-water (110:20:30:100). Both reference sides were cut off and the reference spot were detected with 10% alcoholic phosphomolybdic acid. Distribution of smooth muscle stimulating activities on the remaining region of the plate was demonstrated as mentioned above. This procedure gives fraction XII.

Bioassay—The isolated organs were suspended in a bath of controlled temperature, oxigenated with air. The movements were recorded isotonically on a smoked drum with a linear frontal writing lever. Uterus Ringer solution was used for isolated uterus and Tyrode solution for other isolated organs. Compositions of these solutions are as follows: Uterus Ringer solution: NaCl 0.9%, KCl 0.02%, CaCl<sub>2</sub> 0.004%, NaHCO<sub>3</sub> 0.05% and glucose 0.05%. Tyrode solution: NaCl 0.8%, KCl 0.02%, CaCl<sub>2</sub> 0.02%, MgCl<sub>2</sub> 0.0093%, NaHCO<sub>3</sub> 0.1%, NaH<sub>2</sub>PO<sub>4</sub> 0.004%, and glucose 0.1%. Experiments *in vivo* were performed on rabbits and rats anesthetized with urethane (2 g/kg body weight s.c.). The trachea was canulated and arterial blood pressure was measured by means of mercury manometer.

Acknowledgement We thank the Kanonji Institute, the Research of Foundation for Microbial Deseases of Osaka University for presentation of monkey lungs, and the Institute of Ono Pharmaceutical Industries, LTD. for presentation of authentic samples.

Chem. Pharm. Bull. 18(1) 209-210 (1970)

UDC 547.94.02:547.918.02

## On the Structure of Morphine-6-glucuronide in a Solid State

KAZUTA OGURI, HIDETOSHI YOSHIMURA, and HISAO TSUKAMOTO

Faculty of Pharmaceutical Sciences, Kyushu University<sup>1)</sup>

(Received August 1, 1969)

Recently we have reported the first synthesis of morphine-3- and -6-glucuronides together with the synthesis of codeine glucuronide.<sup>2)</sup> It has been subsequently established that both the morphine glucuronides are excreted as the metabolites of morphine in several experimental animals and in human, although the amount of 6-glucuronide excreted is much less than that of 3-isomer.<sup>3,4)</sup> For the pharmaceutical study of these glucuronides, a rather large amount of morphine-6-glucuronide became necessary to be synthesized, and therefore several runs of the synthesis of this glucuronide were carried out by the same method as reported previously.<sup>2)</sup> However, subsequently obtained crystals of morphine-6-glucuronide (I<sub>b</sub>), mp 251—256° (decomp.), exhibited a completely different IR spectrum from that of the former sample (I<sub>a</sub>), mp 254—256° (decomp.). This article reports that 6-glucuronide possesses two different structures in a solid state.

The IR spectrum of  $I_a$  showed a strong peak at 1750 cm<sup>-1</sup> which suggested that  $I_a$  should exist in the structure possessing a non-ionized carboxyl group shown in Fig. 1. On the other

<sup>1)</sup> Location: Katakasu, Fukuoka.

<sup>2)</sup> H. Yoshimura, K. Oguri and H. Tsukamoto, Tetrahedron Letters, 1968, 483; idem, Chem. Pharm. Bull. (Tokyo), 16, 2114 (1968).

<sup>3)</sup> H. Yoshimura, K. Oguri and H. Tsukamoto, Biochem. Pharmacol., 18, 279 (1969).

<sup>4)</sup> H. Yoshimura, S. Îda, K. Oguri, E. Hasegawa and H. Tsukamoto, Meeting of Kyushu Branch, Pharmaceutical Society of Japan, Fukuoka, July 1968.